In one research, researchers have found that an enzyme with a role in huge inflammation can be the main mechanism that is driving COVID-19 severity. It can also provide a target to therapists in reducing the mortality of COVID-19.
Molecular Mechanism For Covid-19 Mortality Identified
The main author of this research is Maurizio Del Poeta, who is an MD of Renaissance school of medicine located at SB university. This research was published in the clinical investigation journal for details.
Researchers of the Arizona University which also collaborated with SB university found blood samples from two coronavirus patients for analyzing the circulation of an enzyme. It can be the main and very important factor while predicting those patients who have severe virus infection of COVID-19. Spla2-IIA, which is similar to the active enzymes in the venom, plays a great role in protection against any bacterial infections.
The virus has this molecular mechanism with several differences and that only decided the severity of the infection in concerned patients. However, as per the experts with the variant and type of molecular mechanism, the immunity of an individual also plays a major role but when the mechanism of this virus is more impactful the immunity may not act as a shield and one may have to face severe medical condition. This virus attacks the lungs and respiratory system first which leads to chronic organ issues over a period in different parts of the body.
“This new study is showing great results and new therapeutic targets which will help to reduce and prevent the mortality of COVID-19. We have identified the new blood marker which can be highly elevated in deceased and severe versus negative or mild COVID-19 patients. It also builds a decision tree with the help of machine learning that also helps clinicians from dying by COVID-19”, said Dr. Del Poeta, who is a co-author in the department of Immunology and Microbiology.
An activated enzyme can be circulated at a high level and it can damage membranes of vital organs, said Floyd Chilton, who is a senior author at the University of Agriculture and Life Sciences.
“It’s a bell-shaped bent infection obstruction versus has resistance,” Chilton said. “All in all, this compound is attempting to kill the infection, yet at one point it is delivered in such high sums that things head in a truly downright awful, obliterating the patient’s cell films and consequently adding to various organ disappointment and passing.”
“The plan to recognize a possible prognostic factor in the COVID-19 patients started from Dr. Chilton,” Del Poeta said. “He originally reached us the previous fall with the plan to break down lipids and metabolites in blood tests of COVID-19 patients.”
Dr. Del Poeta and the group of other researchers from his team collected plasma samples which were stored and went to work to find medical charts while tracking critical data related to clinical purposes from almost 127 patients. All of them were hospitalized between Jan and July 2020. The other clinical research included samples of almost 154 patients collecting it from Banner and Stony Brook University.
“Our study is based on COVID-19 and how it has given the delta variant to rise among people in hospitals in the US and all over the World. It has become essential for us to research it further and get the final result”, Chilton added. One research that was done previously in our lab has shown the results such as how an enzyme can destroy microbial cells and membranes in the infections related to bacteria. It is similar to genetic ancestry with the main enzyme which was found in the venom of snakes
